This morning before the opening bell, Cellceutix Corp. announced that a new animal study of its compound for autism spectrum disorder, KM-391, further demonstrated a positive impact on several measures of behavior associated with autism. As announced by the company last week, Cellceutix expedited the research through a collaborative effort with InterEd Faculty of Clinical Research (IFCR) in India and the prestigious Cochin University of Science & Technology (CUSAT).
In the study, test subjects were injected with a compound to simulate autistic behaviors then injected with an oxytocin antagonist to intensify the symptoms. Test subjects were divided into four groups, oxytocin antagonist only, oxytocin antagonist plus KM-391 (10 mg/kg), placebo alone and placebo plus KM-391 (10 mg/kg). Measurements taken of autism related behaviors included: repetitive behavior, self-induced injury, sensitivity to touch, positioning correction, group dynamics, and curiosity. Through this study it was discovered that when KM-391 was given along with the oxytocin antagonist, there was a significant reduction in all 6 autism-related behaviors within 1 to 2 hours.
“We are extremely excited about the results from this phase of testing as it coincides with the previous research,” stated Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. “Having been involved in the research and development of extremely successful compounds in the past, I am very encouraged by the research results that we are achieving with KM-391 and its development potential as a treatment for autism. In our testing, we have simulated specific characteristics of an autistic brain and behavioral symptoms that result from them. KM-391 has been shown to significantly improve both the physical conditions in the brain and behaviors resulting in our animal models. We now have a basis to expect to emerge as a pharma industry leader in autism.”
“With Pfizer and Novartis recently announcing that they have begun pursuing new treatments for core issues of autism, we are excited to be ahead of the curve,” added Leo Ehrlich, CFO of Cellceutix. “The latest research has significantly strengthened the previous data and this puts Cellceutix in the forefront of autism research. While we have already been receiving notoriety in the industry, we believe that this is just the beginning of great things to come for Cellceutix and its shareholders.”
Facts about autism:
•1 percent of the population of children in the U.S. ages 3-17 have an autism spectrum disorder. Prevalence is estimated at 1 in 110 births.
•More children will be diagnosed with autism this year than with AIDS, diabetes & cancer combined.
•1 to 1.5 million Americans live with an autism spectrum disorder. 1 percent of the adult population of the United Kingdom have an autism spectrum disorder.
•Fastest-growing developmental disability; 10 – 17 % annual growth.
•$60 billion estimated annual cost with 60% of costs in adult services. Cost of lifelong care can be reduced by 2/3 with early diagnosis and intervention.
•Autism receives less than 5% of the current US private research funding, and less than 1% of the total NIH budget, even though it is the most prevalent childhood disorder.
Let us hear your thoughts: Cellceutix Corp. Message Board